Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2012
At a glance
- Drugs Bevacizumab; Gimeracil/oteracil/tegafur; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 28 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 27 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 28 Jul 2010 Planned end date changed from 1 Jun 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.